Prime Medicine, Inc.
PRME
$3.67
$0.020.55%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.63M | 5.98M | 4.96M | 3.85M | 2.98M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.63M | 5.98M | 4.96M | 3.85M | 2.98M |
| Cost of Revenue | 84.77M | 84.17M | 80.52M | 81.52M | 81.39M |
| Gross Profit | -80.14M | -78.19M | -75.56M | -77.68M | -78.41M |
| SG&A Expenses | 52.35M | 49.91M | 52.80M | 52.29M | 50.16M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 212.98M | 209.94M | 209.18M | 210.36M | 205.45M |
| Operating Income | -208.35M | -203.96M | -204.22M | -206.52M | -202.47M |
| Income Before Tax | -201.14M | -197.34M | -199.28M | -202.15M | -195.88M |
| Income Tax Expenses | -- | -- | -- | -134.00K | 0.00 |
| Earnings from Continuing Operations | -201.14 | -197.34 | -199.28 | -202.01 | -195.88 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -201.14M | -197.34M | -199.28M | -202.01M | -195.88M |
| EBIT | -208.35M | -203.96M | -204.22M | -206.52M | -202.47M |
| EBITDA | -201.03M | -196.80M | -197.38M | -200.01M | -196.34M |
| EPS Basic | -1.38 | -1.44 | -1.57 | -1.62 | -1.66 |
| Normalized Basic EPS | -0.87 | -0.91 | -0.98 | -1.02 | -1.06 |
| EPS Diluted | -1.38 | -1.44 | -1.57 | -1.62 | -1.66 |
| Normalized Diluted EPS | -0.87 | -0.91 | -0.98 | -1.02 | -1.06 |
| Average Basic Shares Outstanding | 597.87M | 551.50M | 510.76M | 500.76M | 474.34M |
| Average Diluted Shares Outstanding | 597.87M | 551.50M | 510.76M | 500.76M | 474.34M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |